Business is booming for the maker of specialty digital mammography and x-ray imaging systems. In its second quarter, end July 1, the company reported revenue up $900,000 to $12.8 million compared with $11.9 million for the same quarter last year. Net
Business is booming for the maker of specialty digital mammography and x-ray imaging systems. In its second quarter, end July 1, the company reported revenue up $900,000 to $12.8 million compared with $11.9 million for the same quarter last year. Net income for the quarter was $751,000, or 9¢ per share, compared with $465,000, or 7¢ per share, for the same period last year. For the six months ended July 1, net income increased by 18% to $958,000, compared with a net income of $815,000 for the same period last year, reflecting a third-quarter 2000 one million share equity placement. CFO Rodney B. Johnson credited a streamlining of production processes and reorganization of the sales force for the improved bottom line.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.